Clinical meaning
Cancer is fundamentally a disease of uncontrolled cellular proliferation arising from accumulated genetic mutations that disrupt the normal regulatory mechanisms governing cell growth, differentiation, and death. Understanding the cellular basis of malignancy is essential for practical nurses who care for oncology patients across all clinical settings.
Normal cells progress through the cell cycle -- a tightly regulated series of phases (G1, S, G2, and M phase) governed by cyclins, cyclin-dependent kinases (CDKs), and checkpoint proteins. Tumor suppressor genes (most notably p53, the so-called guardian of the genome, and Rb, the retinoblastoma protein) act as brakes on the cell cycle, halting progression when DNA damage is detected and triggering either DNA repair or apoptosis (programmed cell death). Proto-oncogenes are normal genes that code for proteins promoting cell growth and division; when mutated, they become oncogenes that produce constitutively active growth signals, driving uncontrolled proliferation. Cancer develops when the balance between growth-promoting oncogenes and growth-inhibiting tumor suppressor genes is disrupted, typically requiring multiple mutations (the multi-hit hypothesis).
The hallmarks of cancer describe the acquired capabilities that distinguish malignant cells from normal cells: sustained proliferative signaling (oncogene activation), evasion of growth suppressors (tumor suppressor inactivation), resistance to cell death (defective apoptosis pathways), replicative immortality (activation of telomerase, which prevents the shortening of telomeres that normally limits cell division), induction of angiogenesis (tumors stimulate new blood vessel formation through vascular endothelial growth factor, or VEGF, to supply nutrients and oxygen), and activation of invasion and metastasis (cancer cells break through basement membranes, enter blood vessels or lymphatics, and establish secondary tumors at distant sites).